Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance

University of Zurich (UZH)

Status: Unknown

Conditions: Prostate Cancer

Treatments: Device: Pimonidazol

Study type: Observational

Funder types: Other

Identifier

NCT01191099

Details and patient eligibility

About

A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer

Full description

1. To perform a large scale assessment of tissue hypoxia by pimonidazole and hypoxia marker gene expression in human prostate cancers
2. To characterize expression and hypoxia/HIF-responsiveness of myoglobin, cytoglobin, α-hemoglobin in prostate tumors and cell lines
3. To identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancers

Enrollment: 150 estimated patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with radical prostatectomy at the Department of Urology, University Hospital of Zurich
• Written informed consent

Exclusion criteria

• Metastatic prostate cancer
• Contraindications to the class of investigational product under study, e.g. known hypersensitivity or allergy to the investigational product
• Severe heart or lung disease
• Severe liver or kidney dysfunction
• Severe stridor
• Distant metastases
• Concurrent treatment for other malignant disease
• Prior hormonal therapy or radiotherapy